Author
@MartinShkreli
grade Bx.com/MartinShkreli ↗
Shkreli is a former hedge-fund manager and biotech executive whose recent X feed includes stock-specific short theses such as QUBT, QBTS, and RGTI, and media have documented his po
trader score
-0.77
hit rate
42%
mean α
-1.85%
signals 14d
12
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 12 scored bets: 42% hit rate, -1.85% mean alpha, trader score -0.77. Their last-14d mentions, direction-adjusted, have moved -10.9% since posting (mean over 8 mentions with price data).
Recent signals12receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-01 | SNDK | @MartinShkreli | +0.60 | Recommend buying momentum in MU/SNDK beta selloff — Calls MU and SNDK selloff beta-driven and recommends buying momentum. | -14.1% | tweet ↗ |
| 2026-07-01 | NVDA | @MartinShkreli | +0.20 | Recommend buying momentum in MU/SNDK beta selloff — Calls MU and SNDK selloff beta-driven and recommends buying momentum. | -1.4% | tweet ↗ |
| 2026-07-01 | META | @MartinShkreli | +0.15 | Recommend buying momentum in MU/SNDK beta selloff — Calls MU and SNDK selloff beta-driven and recommends buying momentum. | -4.9% | tweet ↗ |
| 2026-07-01 | MU | @MartinShkreli | +0.60 | Recommend buying momentum in MU/SNDK beta selloff — Calls MU and SNDK selloff beta-driven and recommends buying momentum. | -5.5% | tweet ↗ |
| 2026-07-01 | QCLS | @MartinShkreli | +0.25 | Company-related update says QCLS hired first engineers to build photonic computer. | -2.8% | tweet ↗ |
| 2026-07-01 | LULU | @MartinShkreli | -0.30 | Mocks StanphylCap fund letter performance and positions including long LULU. | +1.7% | tweet ↗ |
| 2026-06-29 | EVMN | @MartinShkreli | +0.70 | Long EVMN on today's drop as a new position. — Explicitly says long EVMN on the drop, new position, with drug-development thesis. | · | tweet ↗ |
| 2026-06-29 | · | @MartinShkreli | · | Posts dated performance of +0.25%, a realized recap with no ticker. | · | tweet ↗ |
| 2026-06-28 | LLY | @MartinShkreli | -0.25 | Sarcastic skepticism toward LLY brenipatide development breadth. | +0.5% | tweet ↗ |
| 2026-06-25 | BCRX | @MartinShkreli | +0.80 | Long idea: BCRX should trade from $10 to $30 — Explicit long idea with sum-of-parts thesis and author price target. | · | tweet ↗ |
| 2026-06-24 | ABVX | @MartinShkreli | -0.25 | Says ABVX has caused headaches, mildly negative holder sentiment. | +56.4% | tweet ↗ |
| 2026-06-21 | · | @MartinShkreli | · | Critical view of biopharma strategy/M&A and techbio as meaningless. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.